WallStSmart

Digital Realty Trust Inc (DLR)vsLineage, Inc. Common Stock (LINE)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Digital Realty Trust Inc generates 9% more annual revenue ($5.84B vs $5.36B). DLR leads profitability with a 24.0% profit margin vs -1.9%. DLR earns a higher WallStSmart Score of 59/100 (C).

DLR

Buy

59

out of 100

Grade: C

Growth: 7.3Profit: 5.5Value: 4.0Quality: 5.5
Piotroski: 5/9Altman Z: 0.75

LINE

Hold

36

out of 100

Grade: F

Growth: 3.3Profit: 3.5Value: 5.0Quality: 3.8
Piotroski: 5/9Altman Z: 0.81
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

DLRUndervalued (+3.4%)

Margin of Safety

+3.4%

Fair Value

$180.65

Current Price

$175.42

$5.23 discount

UndervaluedFair: $180.65Overvalued

Intrinsic value data unavailable for LINE.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

DLR4 strengths · Avg: 9.0/10
EPS GrowthGrowth
60.3%10/10

Earnings expanding 60.3% YoY

Market CapQuality
$55.29B9/10

Large-cap with strong market position

Profit MarginProfitability
24.0%9/10

Keeps 24 of every $100 in revenue as profit

Price/BookValuation
2.7x8/10

Reasonable price relative to book value

LINE1 strengths · Avg: 10.0/10
Price/BookValuation
0.9x10/10

Reasonable price relative to book value

Areas to Watch

DLR4 concerns · Avg: 2.5/10
Return on EquityProfitability
5.8%3/10

ROE of 5.8% — below average capital efficiency

Debt/EquityHealth
1.053/10

Elevated debt levels

PEG RatioValuation
16.182/10

Expensive relative to growth rate

P/E RatioValuation
41.0x2/10

Premium valuation, high expectations priced in

LINE4 concerns · Avg: 2.5/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Return on EquityProfitability
-1.2%2/10

ROE of -1.2% — below average capital efficiency

Revenue GrowthGrowth
-0.2%2/10

Revenue declined 0.2%

Altman Z-ScoreHealth
0.812/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : DLR

The strongest argument for DLR centers on EPS Growth, Market Cap, Profit Margin. Profitability is solid with margins at 24.0% and operating margin at 13.3%. Revenue growth of 11.1% demonstrates continued momentum.

Bull Case : LINE

The strongest argument for LINE centers on Price/Book.

Bear Case : DLR

The primary concerns for DLR are Return on Equity, Debt/Equity, PEG Ratio. A P/E of 41.0x leaves little room for execution misses.

Bear Case : LINE

The primary concerns for LINE are EPS Growth, Return on Equity, Revenue Growth.

Key Dynamics to Monitor

DLR profiles as a mature stock while LINE is a turnaround play — different risk/reward profiles.

DLR is growing revenue faster at 11.1% — sustainability is the question.

LINE generates stronger free cash flow (78M), providing more financial flexibility.

Monitor REIT - SPECIALTY industry trends, competitive dynamics, and regulatory changes.

Bottom Line

DLR scores higher overall (59/100 vs 36/100), backed by strong 24.0% margins and 11.1% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Digital Realty Trust Inc

REAL ESTATE · REIT - SPECIALTY · USA

Digital Realty Trust, Inc. is a real estate investment trust that invests in carrier-neutral data centers and provides colocation and peering services.

Visit Website →

Lineage, Inc. Common Stock

REAL ESTATE · REIT - INDUSTRIAL · USA

Lineage, Inc. (Ticker: LINE) is an innovative biotechnology company at the forefront of regenerative medicine, specializing in the development of advanced cell therapy solutions aimed at treating severe diseases such as eye disorders, spinal cord injuries, and cancer. Leveraging proprietary technologies and a strong commitment to strategic partnerships, the company is dedicated to revolutionizing patient care with its novel therapeutic approaches. As Lineage continues to enhance its diverse product pipeline and accelerate clinical research initiatives, it represents a compelling opportunity for institutional investors looking to support transformative advancements in healthcare.

Visit Website →

Want to dig deeper into these stocks?